Cover Image
市場調查報告書

歐美的胰島素市場:2016∼2020年

Insulin Market in the US and Europe 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 357735
出版日期 內容資訊 英文 95 Pages
訂單完成後即時交付
價格
Back to Top
歐美的胰島素市場:2016∼2020年 Insulin Market in the US and Europe 2016-2020
出版日期: 2016年05月05日 內容資訊: 英文 95 Pages
簡介

第一型糖尿病是免疫系統會攻擊胰臟細胞,造成體內幾乎完全不產生胰島素。第二型糖尿病是身體無法製造足以調節血糖值的胰島素。這些患者必須配合症狀及其他藥劑,每天打胰島素。歐美的胰島素市場在2016∼2020年這段期間預測將以年複合成長率6.17%擴大。

本報告提供歐美胰島素市場現狀與到2020年前的成長預測,彙整市場趨勢與課題,各地區趨勢,主要供應商簡介等資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 主力品牌藥物簡介

第6章 胰島素:概要

  • 胰島素的歷史
  • 流行病學
  • 給付方案
  • 已經過核准產品的專利方案

第7章 產品研發線

第8章 口服胰島素療法

第9章 市場情況

  • 全球胰島素市場
  • 歐美的胰島素市場
  • 市場規模與預測
  • 波特的五力分析

第10章 各類藥物市場區隔

第11章 各用途市場市場區隔

  • 第一型糖尿病
  • 第二型糖尿病

第12章 胰島素給藥技術別市場區隔

  • 注射
  • 口服
  • 吸入
  • 其他新興技術
  • 胰島素幫浦

第13章 各地區市場區隔

  • 美國
  • 歐洲

第14章 推動市場的要素

  • 胰島素給藥技術的進步
  • 醫療的未滿足需求
  • 糖尿病及肥胖罹患率的上升
  • 糖尿病的意識提升

第15章 促進要素的影響

第16章 市場課題

  • 胰島素產生的複雜
  • 保管狀態的不足和流通政策
  • 嚴格的法律制度
  • 給藥途徑不便

第17章 促進要素與課題的影響

第18章 市場趨勢

第19章 供應商環境

  • 競爭模式
  • 市場佔有率分析:2015年
  • Sanofi
  • Novo Nordisk
  • Eli Lilly
  • 其他值得注意的供應商

第20章 附錄

第21章 關於Technavio

圖表

目錄
Product Code: IRTNTR9349

About Insulin

Beta cells of the pancreas produce insulin, a hormone that regulates blood glucose levels, by stimulating cells to absorb glucose from the blood. In the cells, glucose is converted into energy, which is used by tissues and muscles to perform their physiological functions. This process is restricted in people with diabetes, resulting in the accumulation of glucose in the blood. This condition is known as hyperglycemia; it damages body tissues over a period, leading to life-threatening health complications such as diabetic retinopathy and diabetic nephropathy. In type 1 diabetes or gestational diabetes, the immune system attacks the pancreatic cells, resulting in little or no insulin production. In type 2 diabetes, the body does not produce sufficient insulin to regulate blood glucose levels. In both type 1 and type 2 diabetes, the individual requires daily doses of insulin along with other medications, depending on the condition. Different types of insulin products, such as human insulin and insulin analogs, are available for insulin replacement therapy.

Technavio's analysts forecast the insulin market in the US and Europe to grow at a CAGR of 6.17% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the insulin market in the US and Europe for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the branded drugs during the forecast period.

The market is divided into the following segments based on geography:

  • US
  • Europe

Technavio's report, Insulin Market in the US and Europe 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Sanofi
  • Novo Nordisk
  • Eli Lilly

Other Prominent Vendors

  • Adocia
  • Biocon
  • Biodel
  • Biogenomics
  • Boehringer Ingelheim
  • Dance Biopharm
  • Diasome Pharmaceuticals
  • Exsulin
  • Generex
  • Lexicon Pharmaceuticals
  • Ligand Pharmaceuticals
  • MannKind
  • Macrogenics
  • Merck
  • Melior Pharmaceuticals
  • Metabolic Solutions Development Company
  • NGM Biopharmaceuticals
  • NuSirt Biopharma
  • Oramed Pharmceuticals
  • PhaseBio Pharmaceuticals
  • Pfizer
  • Thermalin Diabetes
  • Tolerion
  • VeroScience
  • vTv Therapeutics
  • Wockhardt
  • XOMA

Market driver

  • Advances in insulin delivery technology
  • For a full, detailed list, view our report

Market challenge

  • Complexity of insulin production
  • For a full, detailed list, view our report

Market trend

  • Increasing price of insulin drugs
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Assumptions:
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights
  • Key buying criteria

PART 05: Major branded drug profiles

  • Actrapid
  • Apidra
  • Humalog
  • Insuman
  • Lantus
  • Levemir
  • NovoMix
  • NovoRapid
  • Toujeo
  • Tresiba

PART 06: Insulin: An overview

  • History of insulin
  • Epidemiology
  • Reimbursement scenario
  • Patent scenario for approved products

PART 07: Pipeline portfolio

  • Xultophy (NN9068)
  • Faster-acting insulin aspart (NN1218)
  • SAR342434
  • LY2605541
  • MK-1293
  • Oral-Lyn

PART 08: Oral insulin therapies

  • Upcoming vendors for oral insulin therapies
  • Oramed Pharmaceuticals
  • Generex Biotechnology

PART 09: Market landscape

  • Global insulin market
  • Insulin market in US and Europe
  • Market size and forecast
  • Five forces analysis

PART 10: Market segmentation by drug class

  • Fast-acting insulin
  • Intermediate-acting insulin
  • Long-acting insulin

PART 11: Market segmentation by application

  • Type 1 diabetes
  • Type 2 diabetes

PART 12: Market segmentation by insulin delivery technologies

  • Injectable insulin
  • Oral insulin
  • Inhaled insulin
  • Other emerging insulin delivery technologies
  • Insulin pumps

PART 13: Geographical segmentation

  • Insulin market in US
  • Insulin market in Europe

PART 14: Market drivers

  • Advances in insulin delivery technology
  • Unmet medical needs
  • Increase in prevalence of diabetes and obesity
  • Increase in awareness of diabetes

PART 15: Impact of drivers

PART 16: Market challenges

  • Complexity of insulin production
  • Poor storage condition and distribution policies
  • Stringent regulatory environment
  • Inconvenient ROA

PART 17: Impact of drivers and challenges

PART 18: Market trends

  • Increase in R&D for novel mechanisms
  • Increase in academia-industry collaborations for drug development
  • Increasing price of insulin drugs
  • Intense competition among present and upcoming vendors

PART 19: Vendor landscape

  • Competitive scenario
  • Market share analysis 2015
  • Sanofi
  • Novo Nordisk
  • Eli Lilly
  • Other prominent vendors

PART 20: Appendix

  • List of abbreviations

PART 21: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Key buying criteria for insulin
  • Exhibit 03: History of insulin development
  • Exhibit 04: Incidence of diabetes among ethnic groups in US 2014
  • Exhibit 05: Diagnosed and undiagnosed diabetes in US by gender 2012
  • Exhibit 06: Diagnosed and undiagnosed diabetes in people aged 20 years or older in US 2012
  • Exhibit 07: Diabetes in people aged 20-79 years in Europe 2013 and 2035
  • Exhibit 08: Proportion of diabetes in top countries of Europe 2013 (millions)
  • Exhibit 09: Diabetes in Europe among people aged 20-79 years by gender 2014
  • Exhibit 10: Approved product portfolio
  • Exhibit 11: Pipeline portfolio: Insulin market in US and Europe
  • Exhibit 12: Share of pipeline products in insulin market in US and Europe by stage of development 2015
  • Exhibit 13: Pipeline share of top companies in insulin market in US and Europe
  • Exhibit 14: Oramed Pharmaceuticals: Pipeline products
  • Exhibit 15: Global insulin market 2015-2020 ($ billions)
  • Exhibit 16: Market share of global insulin drugs in global pharmaceutical market 2015
  • Exhibit 17: Global insulin market in the US and Europe 2015-2020 ($ billions)
  • Exhibit 18: Five forces analysis
  • Exhibit 19: Segmentation of insulin market in US and Europe by drug class
  • Exhibit 20: Market share of insulin in US and Europe by drug class
  • Exhibit 21: Marketed insulin formulations
  • Exhibit 22: Insulin market in US and Europe by application 2015
  • Exhibit 23: Insulin delivery technologies
  • Exhibit 24: Insulin pumps market in US 2015-2020 ($ millions)
  • Exhibit 25: Insulin pumps market in Europe 2015-2020 ($ millions)
  • Exhibit 26: Geographical segmentation of insulin market in US and Europe 2015
  • Exhibit 27: Insulin market in US 2015-2020 ($ billions)
  • Exhibit 28: Market share of insulin in US by drug class 2015
  • Exhibit 29: Insulin market in Europe 2015-2020 ($ billions)
  • Exhibit 30: Market share of insulin in Europe by drug class 2015
  • Exhibit 31: Unmet medical needs in insulin market in US and Europe
  • Exhibit 32: Impact of drivers
  • Exhibit 33: Impact of drivers and challenges
  • Exhibit 34: Market share analysis 2015
  • Exhibit 35: Revenue share of major companies for insulin market in US and Europe 2015
  • Exhibit 36: Revenues from the sales of top five products in insulin market in US and Europe 2013-2015 ($ billions)
  • Exhibit 37: Sanofi: YoY revenue and growth rate of Lantus 2013-2015 ($ billions)
  • Exhibit 38: Sanofi: Geographical segmentation of Lantus 2015
  • Exhibit 39: Sanofi: YoY revenue and growth rate of Apidra 2013-2015 ($ millions)
  • Exhibit 40: Sanofi: Geographical segmentation of Apidra 2015
  • Exhibit 41: Sanofi: Geographical segmentation of Toujeo 2015
  • Exhibit 42: Sanofi: YoY revenue and growth rate of Insuman 2013-2015 ($ millions)
  • Exhibit 43: Sanofi: Geographical segmentation of Insuman 2015
  • Exhibit 44: Sanofi: Key takeaways
  • Exhibit 45: Novo Nordisk: YoY growth and revenue of NovoLog/NovoRapid 2013-2015 ($ billions)
  • Exhibit 46: Novo Nordisk: Geographical segmentation of revenues of NovoLog 2015
  • Exhibit 47: Novo Nordisk: YoY growth and revenue of NovoMix/NovoLog mix 2013-2015 ($ billions)
  • Exhibit 48: Novo Nordisk: Geographical segmentation of revenues of NovoMix 2015
  • Exhibit 49: Novo Nordisk: YoY revenue and sales growth of Levemir 2013-2015 ($ billions)
  • Exhibit 50: Geographical segmentation of Levemir 2015
  • Exhibit 51: Novo Nordisk: YoY revenue and growth rate of human insulins 2013-2015 ($ billions)
  • Exhibit 52: Geographical segmentation of human insulins 2015
  • Exhibit 53: Novo Nordisk: Key takeaways
  • Exhibit 54: Eli Lilly: YoY revenue and growth rate of Humalog 2013-2015 ($ billions)
  • Exhibit 55: Eli Lilly: Geographical segmentation of Humalog 2015
  • Exhibit 56: Eli Lilly: YoY revenue and growth rate of Humulin 2013-2015 ($ billions)
  • Exhibit 57: Eli Lilly: Geographical segmentation of Humalog 2015
  • Exhibit 58: Eli Lilly: Key takeaways
Back to Top